Price movement over the last 24 hours
ADMA Biologics Inc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.65. The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | HYG | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Fixed Income |
52-Week High | $20.38 | $81.32 |
52-Week Low | $7.60 | $78.72 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
HYG trades at $79.87, up 0.2% today, with a neutral technical signal. The ETF shows consistent dividend distributions, including $0.42 in May 2026. Bond ETF inflows are surging 60% year-over-year as investors seek yield amid market volatility and Fed uncertainty, according to CNBC on June 25, 2026. Technical indicators show mixed signals with bearish moving averages but neutral oscillators.
Outlook remains cautious due to interest rate sensitivity and inflation concerns. Risks include potential Fed rate hikes and narrowing market breadth. The high-yield sector faces pressure from bearish bets, but demand for yield provides support. Investors should weigh income stability against macroeconomic headwinds.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →